Back to Rare Disease
NCT00303329
NCT00303329
Who may be able to join
Who might be able to join this trial:
- You must have already completed the full 12-month main part of this study.
- Female patients who have started their periods and are sexually active must be using two forms of contraception (such as two barrier methods, or a barrier method plus the pill), or must have had a hysterectomy, removal of the ovaries, or tubal ligation ("tubes tied").
- You (and/or your parent or legal guardian, if applicable) must have signed a written consent form agreeing to take part, following the rules of the country where the trial is taking place.
Who may not be able to join:
- You cannot take part if you are currently pregnant.
- You cannot take part if you are currently breastfeeding.
Important: There may be additional eligibility requirements not listed here that the trial team will need to check — always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Novartis Pharmaceuticals
Registry
clinicaltrials_gov
Start date
1 March 2004
Est. completion
1 October 2008
Where this trial is recruiting
🇧🇪 Belgium
🇨🇦 Canada
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇬🇧 United Kingdom
🇺🇸 United States
Primary endpoints
The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.